3D render of a male head showing brain

Clinical Trial Update: Therapeutic Strategies to Delay Disease Progression

Program Overview

In this module of a Four-Part Expert Interview Series, Dr. Marc E. Agronin, along with Dr. Richard S. Isaacson, course chair, will evaluate available therapeutic options for Alzheimer’s disease (AD) patient. The faculty will highlight the evolution of failed and existing therapies in AD, and their impact on current clinical care, emphasizing strategies for delaying disease progression in the modern day. Emerging therapies for the treatment and management of Alzheimer’s disease will also be assessed. Through completing this educational activity, learners will be better acquainted with emerging and emerged clinical trial data as it relates to AD care.

Target Audience

Neurologists, internists, nurse practitioners, nurses, and other healthcare professionals involved in the management of patients with Alzheimer’s disease.

Learning Objectives

I. Analyze clinical trial data of emerging therapeutics to delay progression in the treatment of AD

II. Implement shared decision making with the multidisciplinary team and patients/caregivers to develop individualized treatment plans and referral to clinical studies to advance treatment and improve the quality of life for patients with AD


Isaacson Head ShotRichard S. Isaacson, MD
Associate Professor of Neurology
Director, Alzheimer’s Prevention Clinic
Weill Cornell Medicine
New York Presbyterian Hospital
New York, New York



Marc Agronin, MD (2015)Marc E. Agronin, MD
Vice President, Behavioral Health and Clinical Research
Miami Jewish Health
Affiliate Associate Professor of Psychiatry and Neurology
University of Miami Miller School of Medicine
Miami, Florida


Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity.

FacultyRelationship Identified With:
Richard S. Isaacson, MDConsultant/Advisor: Eli Lilly and Company; Neurotrack; 23 and Me
Marc E. Agronin, MDConsultant/Advisor: Eli Lilly and CompanySpeaker’s Bureau: Allergan

Planners, Managers, Reviewers

Timothy Hayes, MD, PhD; Emma Boring; Nicole Brestowski, Chelsey Benedek and Kim Cheramie, MSN, RN-BC hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercials interest related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AcademicCME is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation

Credit Designation Statement

AcademicCME designates this enduring material for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AcademicCME designates this enduring material for a maximum of .50 CNE contact hours (.50 CNE pharmacotherapeutic contact hours).

Financial Support

This activity has been supported by an independent educational grant from Biogen.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Biogen do not recommend the use of any agent outside of the labeled indications.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions.
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Healthcare providers who receive a grade of 66% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME/CNE Certificate.
  6. All other participants who receive a grade of 66% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
  7. Healthcare providers should claim only the credit commensurate with the extent of their participation in the activity.
  8. 60 minutes of participation = 1 CNE contact hour

CE Inquiries/Special Needs

For all CME/CNE inquiries or special needs, please contact [email protected].